NEW
YORK, Aug. 4, 2023 /PRNewswire/
-- Jakubowitz Law announces that a securities
fraud class action lawsuit has commenced on behalf of
shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/aldeyra-class-action-loss-submission-form/?id=42964&from=4
The lawsuit seeks to recover losses for shareholders who
purchased Aldeyra between March 17,
2022 and June 20, 2023.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
September 29, 2023 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
According to a filed complaint, Aldeyra Therapeutics, Inc.
issued materially false and/or misleading statements and/or failed
to disclose that: (i) the ADX-2191 new drug application ("NDA") did
not include adequate and well-controlled investigations and thus
failed to show substantial evidence of ADX-2191's effectiveness;
(ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA
in its current form; (iii) accordingly, the Company had overstated
ADX-2191's clinical and/or commercial prospects; and (iv) as a
result, the Company's public statements were materially false and
misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/aldx-shareholder-alert-jakubowitz-law-reminds-aldeyra-shareholders-of-a-lead-plaintiff-deadline-of-september-29-2023-301893236.html
SOURCE Jakubowitz Law